PMID- 35693622
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 14
IP  - 5
DP  - 2022 May
TI  - The sST2 level is an independent influencing factor associated with atrial 
      fibrillation in heart failure patients: a case-control study.
PG  - 1578-1587
LID - 10.21037/jtd-22-470 [doi]
AB  - BACKGROUND: Most heart failure (HF) patients were complicated with atrial 
      fibrillation (AF). Previous study has reported a correlation between soluble 
      suppression of tumorigenicity 2 (sST2) and HF. While the association between sST2 
      and AF in HF patients remains elusive, which will strengthen our understanding of 
      sST2 in HF patients. METHODS: In the study, a case-control study was conducted 
      with 306 HF patients enrolled from June 2019 to June 2020 at Beijing Anzhen 
      Hospital. All the patients were divided into the following two groups, based on 
      whether they AF complications prior to admission: (I) the HF group (patients with 
      HF alone) and the HF-AF group (HF patients complicated with AF). Baseline data 
      and sST2 levels were assessed and compared between the two groups, and the 
      influencing factors associated with AF in HF patients were screened. RESULTS: The 
      sST2 level in the HF-AF group was 40.6 (25.9-53.6) ng/mL, which was significantly 
      higher than that in the HF group [23.7 (16.3-35.9) ng/mL] (P<0.001). Correlation 
      analysis showed that sST2 level in the HF-AF group was positively correlated with 
      age (r=0.287, P=0.001), New York Heart Association (NYHA) grade (r=0.470, 
      P<0.0001), left ventricular diameter (LVD) (r=0.311, P=0.001), serum creatinine 
      (r=0.320, P<0.0001), NT-pro-brain natriuretic peptide (r=0.540, P<0.0001), and 
      D-dimer (r=0.322, P<0.0001), and negatively correlated with left ventricular 
      ejection fraction (LVEF) (r=-0.259, P=0.004), hemoglobin (r=-0.188, P=0.039), and 
      glomerular filtration rate (r=-0.283, P=0.002). Logistic regression analysis 
      results indicated that history of coronary heart disease [odds ratio (OR): 0.176, 
      95% confidence interval (CI): 0.081-0.380, P<0.0001], LVEF (OR: 0.956, 95% CI: 
      0.915-0.998, P=0.039), LVD (OR: 1.156, 95% CI: 1.059-1.261, P=0.001), left 
      arterial diameter (OR: 0.761, 95% CI: 0.695-0.833, P<0.0001), and sST2 (OR: 
      0.942, 95% CI: 0.917-0.967, P<0.0001) were independent influencing factors 
      associated with AF in HF patients. CONCLUSIONS: The sST2 level is an independent 
      influencing factor associated with AF in HF patients, which may favor to optimize 
      the clinical strategies in the management of HF patients complicated with AF.
CI  - 2022 Journal of Thoracic Disease. All rights reserved.
FAU - Yan, Xianliang
AU  - Yan X
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Chaoyang, Beijing, 
      China.
FAU - Guo, Yanqing
AU  - Guo Y
AD  - Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
FAU - Wang, Zhixin
AU  - Wang Z
AD  - Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
FAU - Li, Zhizhong
AU  - Li Z
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing Institute of Heart Lung and Blood Vessel Diseases, Chaoyang, Beijing, 
      China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC9186244
OTO - NOTNLM
OT  - Soluble suppression of tumorigenicity 2 (sST2)
OT  - atrial fibrillation (AF)
OT  - heart failure (HF)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-22-470/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/06/14 06:00
MHDA- 2022/06/14 06:01
PMCR- 2022/05/01
CRDT- 2022/06/13 03:17
PHST- 2022/03/21 00:00 [received]
PHST- 2022/05/13 00:00 [accepted]
PHST- 2022/06/13 03:17 [entrez]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/14 06:01 [medline]
PHST- 2022/05/01 00:00 [pmc-release]
AID - jtd-14-05-1578 [pii]
AID - 10.21037/jtd-22-470 [doi]
PST - ppublish
SO  - J Thorac Dis. 2022 May;14(5):1578-1587. doi: 10.21037/jtd-22-470.